ACECHUA的个人主页 - 老虎社区

ACECHUA

ACECHUA

暂无个人介绍

IP属地：未知

497关注

7粉丝

0主题

0勋章

2021-11-02

//@Sorrie2u:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! $Tiger Brokers(TIGR)$

@小虎活动:A BIG BIG November for Tiger Brokers!!

2021-11-12

$Exelixis(EXEL)$up up up

The Smartest Stocks to Buy With $20 Right Now

2021-11-11

$Tiger Brokers(TIGR)$for sharing

2021-11-02

Great ariticle, would you like to share it?

@Blitzery:$Tiger Brokers(TIGR)$ reposting yesterday screenshot for some who may have missed it please. [微笑]

2021-11-12

$Sea Ltd(SE)$For coins

2021-11-11

$Sea Ltd(SE)$For coins

2021-11-09

$Exelixis(EXEL)$For coins

2021-11-09

$Exelixis(EXEL)$For coins

2021-11-06

$Exelixis(EXEL)$For coins

2021-11-03

$Takung Art Co., Ltd.(TKAT)$For coins

2021-11-03

$Takung Art Co., Ltd.(TKAT)$For coins

2021-11-02

$Exelixis(EXEL)$For coins

2021-10-29

$Robinhood Markets, Inc.(HOOD)$For coins

2021-10-21

$ProShares Bitcoin Strategy ETF(BITO)$Forcoins

2021-10-13

$NovoCure(NVCR)$For coins

2021-10-07

$NVIDIA Corp(NVDA)$For coins

2021-10-06

$Exelixis(EXEL)$For coins

2021-10-04

$Exelixis(EXEL)$For coins

2021-10-02

$Exelixis(EXEL)$For coins

2021-11-23

For sharing

Brokers' take: DBS raises Sea TP to US$402 on higher valuation from e-commerce business

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3583096540214259,"uuid":"3583096540214259","gmtCreate":1620002516702,"gmtModify":1620095935995,"name":"ACECHUA","pinyin":"acechua","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":7,"headSize":497,"tweetSize":116,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.03","exceedPercentage":"93.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.03.09","exceedPercentage":"94.00%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":875229827,"gmtCreate":1637659475829,"gmtModify":1637659475897,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"For sharing&nbsp;","listText":"For sharing&nbsp;","text":"For sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875229827","repostId":"1162714912","repostType":2,"isVote":1,"tweetType":1,"viewCount":598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879676697,"gmtCreate":1636724490013,"gmtModify":1636724490221,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>up up up&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>up up up&nbsp;","text":"$Exelixis(EXEL)$up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879676697","repostId":"2182094779","repostType":2,"repost":{"id":"2182094779","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879671817,"gmtCreate":1636724188125,"gmtModify":1636724188125,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Time to buy&nbsp;","listText":"Time to buy&nbsp;","text":"Time to buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879671817","repostId":"2182094779","repostType":2,"repost":{"id":"2182094779","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":752,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879128216,"gmtCreate":1636692717134,"gmtModify":1636692717312,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","text":"$Sea Ltd(SE)$For coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879128216","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870537369,"gmtCreate":1636632317081,"gmtModify":1636632317296,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>for sharing&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>for sharing&nbsp;","text":"$Tiger Brokers(TIGR)$for sharing","images":[{"img":"https://static.tigerbbs.com/41e896f69b303bd84a5e283bb8538d0f","width":"1125","height":"3853"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870537369","isVote":1,"tweetType":1,"viewCount":673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},{"id":870532870,"gmtCreate":1636631931153,"gmtModify":1636631931321,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","text":"$Sea Ltd(SE)$For coins","images":[{"img":"https://static.tigerbbs.com/24d1ef16b7a67357c31cc8197e4171ad","width":"1125","height":"3853"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870532870","isVote":1,"tweetType":1,"viewCount":455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847031724,"gmtCreate":1636467262280,"gmtModify":1636467262472,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Good news !","listText":"Good news !","text":"Good news !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847031724","repostId":"844753603","repostType":1,"repost":{"id":844753603,"gmtCreate":1636463370820,"gmtModify":1636464496982,"author":{"id":"3565400297091055","authorId":"3565400297091055","name":"Kianyong","avatar":"https://static.tigerbbs.com/3e6f88c81a9c942582a9846005398e04","crmLevel":6,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>https://www.theedgesingapore.com/news/markets/tiger-brokers-becomes-sgxs-newest-member-securities-trading-and-clearing-derivatives","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>https://www.theedgesingapore.com/news/markets/tiger-brokers-becomes-sgxs-newest-member-securities-trading-and-clearing-derivatives","text":"$老虎证券(TIGR)$https://www.theedgesingapore.com/news/markets/tiger-brokers-becomes-sgxs-newest-member-securities-trading-and-clearing-derivatives","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844753603","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":569,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844749777,"gmtCreate":1636464175867,"gmtModify":1636464291458,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/b4865b1c67099254eebd4effbea0b554","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844749777","isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844749543,"gmtCreate":1636464156575,"gmtModify":1636464290678,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/4b9606431c6a1df19c2c53583f74c45c","width":"1125","height":"3355"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844749543","isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845205104,"gmtCreate":1636338197825,"gmtModify":1636338197988,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","text":"$Robinhood Markets, Inc.(HOOD)$For coins","images":[{"img":"https://static.tigerbbs.com/dbb7d1e915cd185f9c07ecbc52631fcd","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845205104","isVote":1,"tweetType":1,"viewCount":626,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845205971,"gmtCreate":1636338176093,"gmtModify":1636338176304,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","text":"$Robinhood Markets, Inc.(HOOD)$For coins","images":[{"img":"https://static.tigerbbs.com/2f4163fb157c458a5c374b40b0eb675f","width":"1125","height":"3943"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845205971","isVote":1,"tweetType":1,"viewCount":126,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":845166184,"gmtCreate":1636306791060,"gmtModify":1636306791279,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/845166184","isVote":1,"tweetType":1,"viewCount":249,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842892298,"gmtCreate":1636160280564,"gmtModify":1636160280729,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/0eb52443ee1d9a3f0a8ef1a29229a4fa","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842892298","isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842000070,"gmtCreate":1636118881770,"gmtModify":1636119029090,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>For coins&nbsp;","text":"$NIO Inc.(NIO)$For coins","images":[{"img":"https://static.tigerbbs.com/9639fc62e79e0f5a34b6d07e39907ce3","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842000070","isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":848010956,"gmtCreate":1635947727060,"gmtModify":1635947814566,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848010956","repostId":"841774404","repostType":1,"repost":{"id":841774404,"gmtCreate":1635946578608,"gmtModify":1635946587632,"author":{"id":"3572144449903402","authorId":"3572144449903402","name":"jasonstar","avatar":"https://static.tigerbbs.com/1854384d422f0c85d210c3ea76148814","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>will help?","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>will help?","text":"$Tiger Brokers(TIGR)$will help?","images":[{"img":"https://static.tigerbbs.com/b89c00ee060cd66127083f0653667411","width":"1073","height":"1012"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841774404","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":222,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":841494683,"gmtCreate":1635931674654,"gmtModify":1635931674804,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","text":"$Takung Art Co., Ltd.(TKAT)$For coins","images":[{"img":"https://static.tigerbbs.com/48c15b6aebe724cdc75f0ca58ead1ce1","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841494683","isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841494044,"gmtCreate":1635931651199,"gmtModify":1635931651407,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","text":"$Takung Art Co., Ltd.(TKAT)$For coins","images":[{"img":"https://static.tigerbbs.com/924551c76798300e468dccffd9a8e394","width":"1125","height":"3355"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841494044","isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843499425,"gmtCreate":1635847145679,"gmtModify":1635847145750,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843499425","repostId":"843569168","repostType":1,"repost":{"id":843569168,"gmtCreate":1635842302164,"gmtModify":1635842302723,"author":{"id":"3578091555231876","authorId":"3578091555231876","name":"Blitzery","avatar":"https://static.tigerbbs.com/bac6c599695ac8c073cc33419fb12a9b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;reposting yesterday screenshot for some who may have missed it please.&nbsp;[微笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;reposting yesterday screenshot for some who may have missed it please.&nbsp;[微笑]&nbsp;","text":"$Tiger Brokers(TIGR)$ reposting yesterday screenshot for some who may have missed it please. [微笑]","images":[{"img":"https://static.tigerbbs.com/b46b72856ae84fa01369a729a814dfe1","width":"1080","height":"2244"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843569168","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843144206,"gmtCreate":1635815086648,"gmtModify":1635815086983,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/a639a020e7965f8f779e2e52daeb5eb5","width":"1125","height":"3460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843144206","isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843062260,"gmtCreate":1635783037673,"gmtModify":1635783338388,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3557997848207595\">@Sorrie2u</a>:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! <a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>","listText":"//<a href=\"https://laohu8.com/U/3557997848207595\">@Sorrie2u</a>:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! <a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>","text":"//@Sorrie2u:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! $Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843062260","repostId":"849165132","repostType":1,"repost":{"id":849165132,"gmtCreate":1635735786222,"gmtModify":1635940231850,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"A BIG BIG November for Tiger Brokers!!","htmlText":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","listText":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","text":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","images":[{"img":"https://static.tigerbbs.com/712b61d31121272b969f444fb51bceac","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/beadd3208c0954546bf3678c4e8cb539","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/ffd58e797fcaf5bd954117499cc47976","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849165132","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":843062260,"gmtCreate":1635783037673,"gmtModify":1635783338388,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"//<a href=\"https://laohu8.com/U/3557997848207595\">@Sorrie2u</a>:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! <a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>","listText":"//<a href=\"https://laohu8.com/U/3557997848207595\">@Sorrie2u</a>:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! <a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>","text":"//@Sorrie2u:i love using tiger brokers. the feature i love most is the tracking of holdings in portfolio and the ease to have portfolio analysis. really surpass every other platforms! $Tiger Brokers(TIGR)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843062260","repostId":"849165132","repostType":1,"repost":{"id":849165132,"gmtCreate":1635735786222,"gmtModify":1635940231850,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/4f487d6799e86204e80dfde72e6040c0","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"A BIG BIG November for Tiger Brokers!!","htmlText":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","listText":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","text":"The year has almost come to an end with only 2 months left, but not for Tiger Brokers. November will be a BIG BIG month for us as we kickstart the Tiger Fintech Fiesta (TFF)!How “Big” is the Tiger Fintech Fiesta (TFF)? Very big, let me show you the 4 “Big”s!Big Event - Singapore Fintech Festival 2021 (SFF) Tiger Brokers is proud to be the silver sponsor of Singapore Fintech Festival 2021 (SFF). What's so fun about this big event is that there will be back-to-back Tiger Live webinars from 8th to 12th November, 7pm every day, to cover various topics about investment!How can we forget about promotion ? The second big will be Big Promotion!Tiger Brokers is constantly challenging the limit, and we always rack our brains to give out better benefits to all traders.As part of the Tiger Fintech Fie","images":[{"img":"https://static.tigerbbs.com/712b61d31121272b969f444fb51bceac","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/beadd3208c0954546bf3678c4e8cb539","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/ffd58e797fcaf5bd954117499cc47976","width":"-1","height":"-1"}],"top":1,"highlighted":2,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/849165132","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879676697,"gmtCreate":1636724490013,"gmtModify":1636724490221,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>up up up&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>up up up&nbsp;","text":"$Exelixis(EXEL)$up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879676697","repostId":"2182094779","repostType":2,"repost":{"id":"2182094779","pubTimestamp":1636723680,"share":"https://www.laohu8.com/m/news/2182094779?lang=&edition=full","pubTime":"2021-11-12 21:28","market":"us","language":"en","title":"The Smartest Stocks to Buy With $20 Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2182094779","media":"Motley Fool","summary":"A small amount of money can go a long way when invested in these top-notch stocks.","content":"<p>Time and again, Wall Street has shown investors the power of patience.</p>\n<p>Over the past 71 years, the broad-based <b>S&amp;P 500</b> has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.</p>\n<p>Best of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.</p>\n<h2>Exelixis</h2>\n<p>One of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer <b>Exelixis</b> (NASDAQ:EXEL).</p>\n<p>Last week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.</p>\n<p>However, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"</p>\n<p>Although the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.</p>\n<p>More importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.</p>\n<p>Additionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.</p>\n<p>It's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.</p>\n<h2>Jushi Holdings</h2>\n<p>Some of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) <b>Jushi Holdings</b> (OTC:JUSHF) makes for a smart buy with $20.</p>\n<p>To start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.</p>\n<p>In relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.</p>\n<p>The reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.</p>\n<p>Something else impressive about Jushi, and <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.</p>\n<p>Jushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.</p>\n<h2>Viatris</h2>\n<p>On the other hand, if value runs through your blood, generic-drug giant <b>Viatris</b> (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.</p>\n<p>Roughly a year ago, Viatris was born from the combination of <b>Pfizer</b>'s established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.</p>\n<p>There were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.</p>\n<p>As a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.</p>\n<p>Beyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.</p>\n<p>Viatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Smartest Stocks to Buy With $20 Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Smartest Stocks to Buy With $20 Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-12 21:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VTRS":"Viatris Inc.","EXEL":"伊克力西斯","JUSHF":"Jushi Holdings Inc."},"source_url":"https://www.fool.com/investing/2021/11/12/the-smartest-stocks-to-buy-with-20-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2182094779","content_text":"Time and again, Wall Street has shown investors the power of patience.\nOver the past 71 years, the broad-based S&P 500 has undergone 38 double-digit percentage corrections. Despite the regularity of these moves lower, every crash and correction throughout this period was eventually erased by a bull market rally. To put things succinctly, if investors buy great companies and allow their investment theses to play out over long periods of time, their chances of building wealth is very high.\nBest of all, with most online brokerages discarding minimum deposit requirements and commission fees, investors can begin or further their trek to financial independence with any amount of cash -- even $20. If you have $20 ready to put to work in the market, and it won't be needed to cover bills or other essential costs, the following trio of companies are the smartest stocks to buy right now.\nExelixis\nOne of the savviest stocks patient investors can buy right now with $20 is cancer-drug developer Exelixis (NASDAQ:EXEL).\nLast week, Exelixis announced its third-quarter operating results, which failed to hit the mark and sent its shares down by more than 10%. Sales of lead-drug Cabometyx were shy of Wall Street's expectations, which caused Exelixis to lower the upper end of its full-year sales outlook. Generally, lowering sales expectations will be met with frowns on Wall Street.\nHowever, this short-term weakness should be viewed as an opportunity, especially with the company's price-to-earnings-growth ratio (PEG ratio) below 0.4. A PEG ratio below 1 is typically considered \"undervalued.\"\nAlthough the landscape for first-line advanced renal cell carcinoma (RCC) is competitive, Cabometyx has demonstrated the ability to grow sales by a sustained double-digit percentage in RCC and advanced hepatocellular carcinoma. On an annual run-rate basis, Cabometyx is pacing more than $1 billion in sales -- and it's not done growing.\nMore importantly, Exelixis' lead drug is being examined in close to six dozen clinical trials as a monotherapy or combination treatment. If even a handful of these trials yield a positive result, label-expansion opportunities and organic growth could send Cabometyx to north of $2 billion in peak annual sales.\nAdditionally, Exelixis' robust cash position ($1.8 billion in cash, cash equivalents, and restricted cash) and healthy operating cash flow have allowed it to reignite its internal research engine. This includes advancing internally developed compounds into phase 1 studies, as well as signing collaboration agreements to potentially expand its cancer-drug pipeline.\nIt's not often you can marry growth and value with the same company, but that's exactly what investors can do with biotech stock Exelixis.\nJushi Holdings\nSome of the most deeply discounted growth stocks can be found in the marijuana industry, which is why U.S. multi-state operator (MSO) Jushi Holdings (OTC:JUSHF) makes for a smart buy with $20.\nTo start with, don't be concerned about a lack of cannabis reform in Washington. While life would undoubtedly be easier for pot stocks if lawmakers would simply follow the overwhelming will of the public and legalize cannabis, allowing individual states to legalize and regulate their pot industries is working fine. Thus far, 36 states have given the green light to weed in some capacity, which is providing growth opportunities for MSOs like Jushi.\nIn relative terms, Jushi is a small fry, with only 26 operating dispensaries at the moment. Comparatively, a handful of MSOs have in the neighborhood of (or more than) 100 open locations. But Jushi isn't about reckless expansion. Its management team favors methodical expansion in core markets. For Jushi, these core states are Pennsylvania, Illinois, and Virginia.\nThe reason management has chosen these states is due to their billion-dollar sales potential (Illinois hit $1 billion in legal pot revenue in 2020) and their limited-license status. In limited-license cannabis markets, regulators purposely limit how many dispensary licenses are issued in total, as well as to a single business. For a smaller player like Jushi, this competitive protection ensures it'll have a fair shot to build up its brand(s) and garner a loyal following in these core markets.\nSomething else impressive about Jushi, and one of the reasons I plan to be a long-term shareholder, is the participation of management and insiders. Of the first $250 million raised by the company, $45 million came from insiders and execs. When leadership has skin in the game right alongside their investors, good things tend to happen.\nJushi is expected to turn the corner to recurring profitability in 2022 and the company's growing sales faster than virtually all other MSOs. The company checks all the appropriate boxes for growth investors.\nViatris\nOn the other hand, if value runs through your blood, generic-drug giant Viatris (NASDAQ:VTRS) is one of the smartest stocks you can buy right now with $20.\nRoughly a year ago, Viatris was born from the combination of Pfizer's established drug unit Upjohn with generic-drug developer Mylan. Due to generic-drug price weakness throughout the industry, the company's first year as a public company has been one to forget. However, this near-term underperformance represents the perfect opportunity for patient investors to nab an exceptionally inexpensive and profitable drug stock.\nThere were a number of reasons Upjohn and Mylan tied the knot. First off, there were clear-cut cost synergies. The company expects to recognize more than $500 million in cost synergies this year, with well over $1 billion in annual cost reductions by 2023.\nAs a combined company, Viatris is also in a better position to tackle its outstanding debt. Through the first six months of 2021, $1.15 billion in debt was repaid. By the end of 2023, $6.5 billion in debt should be repaid, which represents a quarter of the company's combined debt ($26 billion), as of November 2020.\nBeyond just trimming the fat, Viatris should be able to kick-start its internal drug research in 2024 once debt levels are reduced to more favorable levels. Keep in mind that new drug research would come atop existing biosimilar clinical trials, which are expected to generate billions of dollars in future sales.\nViatris won't deliver jaw-dropping growth like Jushi, or even double-digit annual sales upside like Exelixis. But with a steadiness to generic-drug demand and an improving balance sheet, Viatris' forward price-to-earnings ratio below 4 simply doesn't do its stock justice.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870537369,"gmtCreate":1636632317081,"gmtModify":1636632317296,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>for sharing&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>for sharing&nbsp;","text":"$Tiger Brokers(TIGR)$for sharing","images":[{"img":"https://static.tigerbbs.com/41e896f69b303bd84a5e283bb8538d0f","width":"1125","height":"3853"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870537369","isVote":1,"tweetType":1,"viewCount":673,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"CN","totalScore":0},{"id":843499425,"gmtCreate":1635847145679,"gmtModify":1635847145750,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/843499425","repostId":"843569168","repostType":1,"repost":{"id":843569168,"gmtCreate":1635842302164,"gmtModify":1635842302723,"author":{"id":"3578091555231876","authorId":"3578091555231876","name":"Blitzery","avatar":"https://static.tigerbbs.com/bac6c599695ac8c073cc33419fb12a9b","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;reposting yesterday screenshot for some who may have missed it please.&nbsp;[微笑]&nbsp;","listText":"<a href=\"https://laohu8.com/S/TIGR\">$Tiger Brokers(TIGR)$</a>&nbsp;reposting yesterday screenshot for some who may have missed it please.&nbsp;[微笑]&nbsp;","text":"$Tiger Brokers(TIGR)$ reposting yesterday screenshot for some who may have missed it please. [微笑]","images":[{"img":"https://static.tigerbbs.com/b46b72856ae84fa01369a729a814dfe1","width":"1080","height":"2244"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843569168","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":879128216,"gmtCreate":1636692717134,"gmtModify":1636692717312,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","text":"$Sea Ltd(SE)$For coins","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/879128216","isVote":1,"tweetType":1,"viewCount":612,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":870532870,"gmtCreate":1636631931153,"gmtModify":1636631931321,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/SE\">$Sea Ltd(SE)$</a>For coins&nbsp;","text":"$Sea Ltd(SE)$For coins","images":[{"img":"https://static.tigerbbs.com/24d1ef16b7a67357c31cc8197e4171ad","width":"1125","height":"3853"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/870532870","isVote":1,"tweetType":1,"viewCount":455,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844749777,"gmtCreate":1636464175867,"gmtModify":1636464291458,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/b4865b1c67099254eebd4effbea0b554","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844749777","isVote":1,"tweetType":1,"viewCount":873,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":844749543,"gmtCreate":1636464156575,"gmtModify":1636464290678,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/4b9606431c6a1df19c2c53583f74c45c","width":"1125","height":"3355"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844749543","isVote":1,"tweetType":1,"viewCount":620,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":842892298,"gmtCreate":1636160280564,"gmtModify":1636160280729,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/0eb52443ee1d9a3f0a8ef1a29229a4fa","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/842892298","isVote":1,"tweetType":1,"viewCount":392,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841494683,"gmtCreate":1635931674654,"gmtModify":1635931674804,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","text":"$Takung Art Co., Ltd.(TKAT)$For coins","images":[{"img":"https://static.tigerbbs.com/48c15b6aebe724cdc75f0ca58ead1ce1","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841494683","isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":841494044,"gmtCreate":1635931651199,"gmtModify":1635931651407,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/TKAT\">$Takung Art Co., Ltd.(TKAT)$</a>For coins&nbsp;","text":"$Takung Art Co., Ltd.(TKAT)$For coins","images":[{"img":"https://static.tigerbbs.com/924551c76798300e468dccffd9a8e394","width":"1125","height":"3355"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/841494044","isVote":1,"tweetType":1,"viewCount":346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843144206,"gmtCreate":1635815086648,"gmtModify":1635815086983,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/a639a020e7965f8f779e2e52daeb5eb5","width":"1125","height":"3460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843144206","isVote":1,"tweetType":1,"viewCount":230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":854734842,"gmtCreate":1635481457344,"gmtModify":1635481457567,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/HOOD\">$Robinhood Markets, Inc.(HOOD)$</a>For coins&nbsp;","text":"$Robinhood Markets, Inc.(HOOD)$For coins","images":[{"img":"https://static.tigerbbs.com/1eb99bf230f0d947976a0e8a25fef6bd","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/854734842","isVote":1,"tweetType":1,"viewCount":73,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":853667484,"gmtCreate":1634802969849,"gmtModify":1634803354318,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BITO\">$ProShares Bitcoin Strategy ETF(BITO)$</a>Forcoins&nbsp;","listText":"<a href=\"https://laohu8.com/S/BITO\">$ProShares Bitcoin Strategy ETF(BITO)$</a>Forcoins&nbsp;","text":"$ProShares Bitcoin Strategy ETF(BITO)$Forcoins","images":[{"img":"https://static.tigerbbs.com/edcf91fff1660d38c0d814deb4ce3ce0","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853667484","isVote":1,"tweetType":1,"viewCount":193,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":822911667,"gmtCreate":1634084381438,"gmtModify":1634084381640,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVCR\">$NovoCure(NVCR)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVCR\">$NovoCure(NVCR)$</a>For coins&nbsp;","text":"$NovoCure(NVCR)$For coins","images":[{"img":"https://static.tigerbbs.com/2c32c31c64b2445b44cfbf83e5021e23","width":"1125","height":"3460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/822911667","isVote":1,"tweetType":1,"viewCount":459,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":823106683,"gmtCreate":1633593923263,"gmtModify":1633593923448,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVDA\">$NVIDIA Corp(NVDA)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVDA\">$NVIDIA Corp(NVDA)$</a>For coins&nbsp;","text":"$NVIDIA Corp(NVDA)$For coins","images":[{"img":"https://static.tigerbbs.com/5372cd2f89d31fc12f09c9242e93a164","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823106683","isVote":1,"tweetType":1,"viewCount":127,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":829674422,"gmtCreate":1633507794405,"gmtModify":1633507794610,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/73abd4df4025bb4e944b75d2bc8ef3d1","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/829674422","isVote":1,"tweetType":1,"viewCount":30,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":867509068,"gmtCreate":1633289171472,"gmtModify":1633289171720,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins&nbsp;","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/ad8cc17fed72cf277dac83ad60646098","width":"1125","height":"2196"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/867509068","isVote":1,"tweetType":1,"viewCount":47,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":864463828,"gmtCreate":1633139384932,"gmtModify":1633139385114,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins","listText":"<a href=\"https://laohu8.com/S/EXEL\">$Exelixis(EXEL)$</a>For coins","text":"$Exelixis(EXEL)$For coins","images":[{"img":"https://static.tigerbbs.com/49cba46a05ac478d5d49263dc6fa30ed","width":"1125","height":"3460"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/864463828","isVote":1,"tweetType":1,"viewCount":72,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":875229827,"gmtCreate":1637659475829,"gmtModify":1637659475897,"author":{"id":"3583096540214259","authorId":"3583096540214259","name":"ACECHUA","avatar":"https://static.tigerbbs.com/3d6bf1e1542321e4f354a78287c1e560","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"For sharing&nbsp;","listText":"For sharing&nbsp;","text":"For sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875229827","repostId":"1162714912","repostType":2,"repost":{"id":"1162714912","pubTimestamp":1637653295,"share":"https://www.laohu8.com/m/news/1162714912?lang=&edition=full","pubTime":"2021-11-23 15:41","market":"us","language":"en","title":"Brokers' take: DBS raises Sea TP to US$402 on higher valuation from e-commerce business","url":"https://stock-news.laohu8.com/highlight/detail?id=1162714912","media":"businesstimes","summary":"SEA Ltd is expected to see an upside in its revenue due to potential growth in its gaming, e-commerc","content":"<div>\n<p>SEA Ltd is expected to see an upside in its revenue due to potential growth in its gaming, e-commerce and fintech businesses, according to DBS Group Research.\nIn a report on Tuesday (Nov 23), the ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce\">Web Link</a>\n\n</div>\n","source":"lsy1607307803821","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brokers' take: DBS raises Sea TP to US$402 on higher valuation from e-commerce business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrokers' take: DBS raises Sea TP to US$402 on higher valuation from e-commerce business\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 15:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SEA Ltd is expected to see an upside in its revenue due to potential growth in its gaming, e-commerce and fintech businesses, according to DBS Group Research.\nIn a report on Tuesday (Nov 23), the ...</p>\n\n<a href=\"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SE":"Sea Ltd"},"source_url":"https://www.businesstimes.com.sg/companies-markets/brokers-take-dbs-raises-sea-tp-to-us402-on-higher-valuation-from-e-commerce","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162714912","content_text":"SEA Ltd is expected to see an upside in its revenue due to potential growth in its gaming, e-commerce and fintech businesses, according to DBS Group Research.\nIn a report on Tuesday (Nov 23), the brokerage maintained a \"buy\" call on the Singapore-based consumer Internet company and raised the target price from US$390 to US$402, on higher valuation from its e-commerce business.\nShares of Sea last closed at US$299.13 on Nov 23 on the New York Stock Exchange, down US$10.86 or 3.5 per cent.\nThe higher target price is based on an adjustment to fair value per share estimates to US$269, US$100 and US$23 for Sea's e-commerce, gaming and fintech segments, respectively, as opposed to the previous estimates of US$242, US$117 and US$19.\nAnalyst Sachin Mittal is optimistic that Sea's e-commerce business will present a \"hyper-growth story\" based on its 82 per cent revenue CAGR (compound annual growth rate) estimate compared to 72 per cent previously, and a 33 per cent average CAGR offered by other major players.\nMittal attributes the increased CAGR estimate to Shopee's success in Brazil, noting that it became the country's most downloaded shopping app over the last 2 years whereas it took about 5 years for the app to achieve the same in South-east Asia.\nThe analyst also believes Shopee's GMV (gross merchandise value) has been boosted by the pandemic as more consumers opt for online shopping, and expects the app to capture an even larger market share as the pandemic forces more sellers and brands to go online.\nWith Shopee's plans to expand further into the Latin American and European markets, Mittal estimates Shopee's GMV to reach US$64 billion in FY2021 and US$102 billion in FY2022.\nWithin Sea's gaming segment, Mittal sees Garena as a \"cash cow\" as it plays a \"pivotal role\" in supporting the expansion of the other 2 segments. While he believes gaming will continue to grow and generate cash flow, this will be at a slower pace.\n\"Importantly, Garena continues to win market share by expanding into new markets, new games and upgrading features,\" says Mittal.\nHighlighting an increasing uptake of SeaMoney's credit business, he sees potential for the e-wallet service, as well as the app's food-delivery service, to transform Shopee into an everyday app.","news_type":1},"isVote":1,"tweetType":1,"viewCount":598,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}